44
Participants
Start Date
August 21, 2023
Primary Completion Date
December 30, 2026
Study Completion Date
December 30, 2027
Zabadinostat (CXD101) and Geptanolimab
"* Zabadinostat (CXD101) at 20mg twice daily per orally Day 1-5 every 3 weeks~* Geptanolimab at 3mg/kg given intravenously every 2 weeks"
Lenvatinib and Sorafenib
"Clinicians' choice of TKI at corresponding recommended dosage:~* Lenvatinib at 8mg daily for patients with body weight \<60kg or 12mg daily with body weight ≥ 60kg~* Sorafenib at 400mg twice daily"
RECRUITING
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong
ACTIVE_NOT_RECRUITING
School of Biomedical Science, The Chinese University of Hong Kong, Hong Kong
Stephen Chan Lam
OTHER